ArticleAsian journal of andrology2026
Differences in adipose-derived stem cells from rats with various health statuses and their effects in diabetic rats with erectile dysfunction.
Article in Asian journal of andrology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
It is essential to use high-quality adipose-derived stem cells (ADSCs) for clinical applications. The functional characteristics of ADSCs differ in the presence of various health conditions. Specifically, recent studies of the therapeutic effects of ADSCs from individuals with diabetes and no erectile dysfunction (NED-ADSCs), ADSCs from those with diabetes and erectile dysfunction (ED-ADSCs), and normal ADSCs have generated conflicting results. Therefore, we aimed to provide evidence for the clinical utility of ADSCs. Diabetes mellitus (DM) was induced in rats by the intraperitoneal injection of streptozotocin (STZ; 40 mg kg -1 ) following 4 weeks of high-fat diet feeding. After 12 weeks, erectile dysfunction was confirmed using the apomorphine (80 µg kg -1 ) test, and those with diabetes mellitus-related erectile dysfunction (DMED) were randomly assigned to treatment groups. Each group was administered 1 × 10 6 allogeneic ADSCs by injection into the corpus cavernosum; then, erectile function and penile histology were evaluated 28 days later. Of the three ADSCs types injected, normal ADSCs exhibited the strongest proliferation and differentiation capabilities. Following ADSCs treatment, there was an increase in smooth muscle cell number and a higher muscle-to-collagen fiber ratio. The expression of neuronal nitric oxide synthase (nNOS) in the dorsal nerve significantly increased. In addition, proteomic analysis revealed that heat shock protein expression was very low in the diabetic rats, but upregulated by stem cell therapy, which may represent a mechanism for the beneficial effects of ADSCs. Therefore, men with diabetes should consider the early preservation of ADSCs to help prevent the onset of erectile dysfunction (ED).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.